Effects of taxifolin on the activity of angiotensin-converting enzyme and reactive oxygen and nitrogen species in the aorta of aging rats and rats treated with the nitric oxide synthase inhibitor and dexamethasone

Age

Volumn 35, Issue 6, 2013, Pages 2089-2097

  Arutyunyan, Tamara V ^a   Korystova, Antonina F ^a   Kublik, Ludmila N ^a   Levitman, Maria Kh ^a   Shaposhnikova, Vera V ^a   Korystov, Yuri N ^a  

^a INSTITUTE OF THEORETICAL AND EXPERIMENTAL BIOPHYSICS   (Russian Federation)

Author keywords

Aging; Angiotensin converting enzyme; Aorta; Dexamethasone; L NAME; ROS RNS; Taxifolin

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE; HIPPURYLHISTIDYLLEUCINE; N(G) NITROARGININE METHYL ESTER; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TAXIFOLIN;

AGED; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROLYSIS; JUVENILE ANIMAL; MALE; NONHUMAN; OXIDATION; RAT;

AGING; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AORTA, THORACIC; ATHEROSCLEROSIS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GLUCOCORTICOIDS; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITROGEN; PEPTIDYL-DIPEPTIDASE A; QUERCETIN; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 84892494810     PISSN: 01619152     EISSN: 15744647     Source Type: Journal    
DOI: 10.1007/s11357-012-9497-4     Document Type: Article

References (51)

1. Ackermann A, Fernandez-Alfonso MS, Sanchez-de-Rojas R, Ortega T, Paul M, Gonzales C (1998) Modulation of angiotensin-converting enzyme by nitric oxide. Br J Pharmacol 124:291-298
2. Actis-Gorettaa L, Ottaviania JI, Keenb CL, Fragaa CG (2003) nhibition of angiotensin converting enzyme (ACE) activity by flavan-3-ols and procyanidins. FEBS Lett 555:597- 600
3. Actis-Gorettaa L, Ottaviania JI, Fragaa CG (2006) Inhibition of angiotensin converting enzyme activity by flavanol-rich foods. J Agricult Food Chem 54:229-234
4. Basso N, Cini R, Pietrelli A, Ferder L, Terragno NA, Inserra F (2007) Protective effect of long-term angiotensin II inhibition. Am J Physiol Heart Circ Physiol 293:H1351-H1358
5. Braga C, Serra CP, Viana Junior NS, Oliveira AB, Cortes SF, Lombardi JA (2007) Angiotensin-converting enzyme inhibition by Brazilian plants. Fitoterapia 78:353-358
6. Choi H, Leto TL, Hunyady L, Catt KJ, Bae YS, Rhee SG (2008) Mechanism of angiotensin 2-induced superoxide production in cells reconstituted with angiotensin type 1 receptor and the components of NADPH oxidase. J Biol Chem 283:255-267
7. Deschamps JD, Kenyon VA, Holman TR (2006) Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg Med Chem 14:4295-4301
8. Duarte J, Perez-Palencia R, Vargas F, Ocete MA, Perez- Vizcaino F, Zarzuelo A, Tamargo J (2001) Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol 133:117-124
9. Dzau VJ (2001) Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 37:1047-1052
10. Emel'yanov MO, Korystova AF, Kublik LN, Levitman MK, Shaposhnikova VV, Korystov YN (2012) Low doses of ethanol decrease the activity of the angiotensin-convertingenzyme in the aorta of aging rats and rats treated with a nitric oxide synthase inhibitor and dexamethasone. Clin Sci 122:75-81
11. Galisteo M, Garcia-Saura MF, Jimenez R, Villar IC, Zarzuelo A, Vargas F, Duarte J (2004) Effects of chronic quercetin treatment on antioxidant defence system and oxidative status of deoxycorticosterone acetate-salt-hypertensive rats. Mol Cell Biochem 259:91- 99
12. Grassi D, Desideri G, Ferri C (2010) Flavonoids: Antioxidants against atherosclerosis. Nutrients 2:889-902
13. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW (1994) Angiotensin 2 stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148
14. Hamberg M (1976) On the formation of thromboxane B2 and 12L-hydroxy-5, 8,10,14- eicosatetraenoic acid (12 ho-20:4) in tissues from the guinea pig. Biochim Biophys Acta 431:651-654
15. Hansen K, Adsersen A, Smitt UW, Nyman U, Christensen SB, Schwartner C, Wagner H (1996) Angiotensin converting enzyme (ACE) inhibitory flavonoids from Erythroxylum laurifolium. Phytomedicine 2:313-317
16. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, Elis A, Aviram M (1997) Reduced progression of atherosclerosis in apolipoprotein E-deficient mice after consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 17:2744-2752
17. Heeneman S, Sluimer JC, Daemen M (2007) Angiotensinconverting enzyme and vascular remodeling. Circ Res 101:441-454
18. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet 342:1007-1111
19. Hishikawa K, Nakaki T, Fujita T (2005) Oral flavonoid supplementation attenuates atherosclerosis development in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 25:442-446
20. Kameda K, Takaku T, Okuda H, Rimura Y (1987) Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod 50:680-683
21. Kato H, Hou J, Chobanian AV, Brecher P (1996) Effects of angiotensin 2 infusion and inhibition of nitric oxide synthase on the rat aorta. Hypertension 28:153-158
22. Katoh M, Egashira K, Kataoka C, Usui M, Koyanagi M, Kitamoto S, Ohmachi Y, Takeshita A, Narita H (2001) Regression by ACE inhibition of arteriosclerotic changes induced by chronic blockade of NO synthesis in rats. Am J Physiol Heart Circ Physiol 280:H2306- H2312
23. Kim S, Iwao H (2000) Molecular and cellular mechanisms of angiotensin 2-mediated cardiovascular and renal diseases. Pharmacol Rev 52:11-34
24. Kitts DD, Yuan YV, Godin DV (1998) Plasma and lipoprotein lipid composition and hepatic antioxidant status in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Can J Physiol Pharmacol 76:202-209
25. Korystov YN, Emel'yanov MO, Korystova AF, Levitman MK, Shaposhnikova VV (2009) Determination of reactive oxygen and nitrogen species in rat aorta using the dichlorofluorescein assay. Free Radic Res 43:149-155
26. Korystova AF, Emel'yanov MO, Kublik LN, Levitman MK, Shaposhnikova VV, Kim YA, Korystov YN (2012) Distribution of the activity of the angiotensin-converting enzyme in the rat aorta and changes in the activity with aging and by the action of L-NAME. Age 34:821-830
27. Koshihara Y, Neichi T, Murota S, Lao A, Fujimoto Y, Tatsuno T (1984) Caffeic acid is a selective inhibitor for leukotriene biosynthesis. Biochim Biophys Acta 792:92-97
28. Koyanagi M, Egashira K, Kubo-Inoue M, Usui M, Kitamoto S, Tomita H, Shimokawa H, Takeshita A (2000) Role of transforming growth factor-1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. Hypertension 35:86-90
29. Lacaille-Dubois MA, Franck U, Wagner H (2001) Search for potential angiotensin converting enzyme (ACE)-inhibitors from plants. Phytomedicine 8:47-52
30. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG (2002) Role of p47phox in vascular oxidative stress and hypertension caused by angiotensin 2. Hypertension 40:511-515
31. Linz W, Wohlfarta P, Scholkensa BA, Malinskib T, Wiemer G (1999) Interactions among ACE, kinins and NO. Cardiovasc Res 43:549-561
32. Liu D, Homan LL, Dillon JS (2004) Genistein acutely stimulates nitric oxide synthesis in vascular endothelial cells by a cyclic adenosine 3′,5′-monophosphate-dependent mechanism. Endocrinology 145:5532-5539
33. Loizzo MR, Said A, Tundis R, Rashed K, Statti GA, Hufner A, Menichini F (2007) Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated from Ailanthus excelsa (Roxb) (Simaroubaceae). Phytother Res 21:32-36
34. Luchtefeld M, Drexler H, Schieffer B (2003) 5-Lipoxygenase is involved in the angiotensin 2-induced NAD(P)H oxidase activation. Biochem Biophys Res Commun 308:668-672
35. Maron DJ (2004) Flavonoids for reduction of atherosclerotic risk. Curr Atheroscler Rep 6:73-78
36. Mehrabian M, Allayee H (2003) 5-Lipoxygenase and atherosclerosis. Cur Opin Lipidol 14:447-457
37. Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and athological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82-C97
38. Meunier M-T, Villié F, Jonadet M, Bastide J, Bastide P (1987) Inhibition of angiotensin I converting enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Med 53:12-15
39. Miyamoto A, Murata S, Nishio A (2002) Role of ACE and NEP in bradykinin-induced relaxation and contraction response of isolated porcine basilar artery. Naunyn- Schmiedeberg's Arch Pharmacol 365:365-370
40. Morrow JD, Roberts LJ (1996) The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 51:1-9
41. Munzel T, Keaney JF (2001) Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 104:1571- 1574
42. Nandave M, Ojha SK, Arya DS (2005) Protective role of flavonoids in cardiovascular diseases. Nat Prod Radiance 4:166-176
43. Nashel DJ (1986) Is atherosclerosis a complication of long-term corticosteroid treatment. Am J Med 80:925-929
44. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG (1996) Angiotensin IImediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97:1916-1923
45. Reed J (2002) Cranberry flavonoids, atherosclerosis and cardiovascular health. Crit Rev Food Sci Nutr 42:301-316
46. Sampson L, Rimm E, Hollman PC, de Vries JH, Katan MB (2002) Flavonol and flavone intakes in US health professionals. J Am Diet Assoc 102:1414-1420
47. Saruta T (1996) Mechanism of glucocorticoid-induced hypertension. Hypertens Res 19:1-8
48. Serhan CN (1997) Lipoxins and novel aspirin-triggered 15-epilipoxins (ATL): A jungle of cell-cell interactions or a therapeutic opportunity. Prostaglandins 53:107-137
49. Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts ACG, Leufkens HGM, Walker BR (2004) Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 90:859-865
50. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A (1997) Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99:278-287
51. Xu Y-Y, Yang C, Li S-N (2006) Effects of genistein on angiotensin-converting enzyme in rats. Life Sci 24:828- 837